Drugs / INCB099280
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06309394 | May → Jun 2024 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06337162 | May 2024 → May 2027 | hepatocellular carcinoma | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06039384 | Dec 2023 → Apr 2025 | cancer | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04242199 | Sep 2020 → Aug 2024 | cervical cancer, cutaneous neuroendocrine carcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma +5 | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05949632 | Apr 2024 → Jun 2025 | cancer | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT05879822 | Oct 2023 → Sep 2026 overdue | neoplasm | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05888844 | Oct 2023 → Sep 2026 overdue | skin squamous cell carcinoma | Incyte Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB099280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06309394 ↗ |
| Action | Inhibit | “PD-L1 inhibitor” NCT06337162 ↗ |
| Route | Oral | “administered orally” NCT04242199 ↗ |